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The in vitro erythromycin-binding properties of bovine alpha-i-acid glycoprotein (AAG) and albumin were
studied by using equilibrium dialysis. In addition, the proportions of free erythromycin in bovine serum and
tissue chamber fluid before and 4 days after inoculation of subcutaneous tissue chambers with Pasteurella
haemolytica were measured. At a concentration of 5 jig/ml, erythromycin was moderately bound to AAG (39%o
4% free) and was only slightly bound to albumin (86%o + 2% free). Scatchard analysis of the data describing
binding to pure bovine AAG indicated that erythromycin was bound to a single high-affinity (6.45 x 104 M-1)
site on the protein. At lower total concentrations of erythromycin, the free concentrations of the antibiotic were
lower in serum samples collected after infection (49% +± 3% at 5 ,ug of erythromycin per ml) than in those
collected before inoculation (55% 3% at 5 ,ug of erythromycin per ml). Inoculation had no eflect on binding
to macromolecules in chamber fluids. Inoculated tissue chambers served as a convenient model for studying
the eflect of infection on drug-macromolecule interactions in interstitial fluid.
In vivo antibacterial efficacy is determined by a number of
factors including the level of penetration of the antibacterial
agent into tissue and the antibacterial activity at the site of
infection. Binding to serum proteins usually results in relatively
higher total concentrations of drug in plasma because the area
under the concentration-time curve from time zero to infinity
(AUC}O) of free drug in plasma is equivalent to the AUCO,
of free drug in the periphery. Protein-bound drugs are too
large to pass through capillary endothelial layers and are
therefore restricted to the circulatory compartment, away from
the site of most infections. Furthermore, there is reliable
evidence indicating that drugs that are protein bound are not
pharmacologically active (22, 26, 27).
Albumin is quantitatively the most important serum protein,
and its effect on the disposition of acidic antibacterial agents is
well established (20). Although alpha-i-acid glycoprotein
(AAG) has a high affinity for basic drugs, the concentrations of
this acute-phase protein in healthy animals are usually too low
to affect drug disposition or efficacy. Consequently, basic drugs
are usually poorly protein bound in healthy animals. For
example, the organic base erythromycin has been reported to
be only 20% bound to bovine serum (28). However, the
concentrations of AAG in serum may increase considerably
during periods of inflammation or infection, and this may
cause an associated increase in the binding of basic drugs (21).
During these periods, when antibacterial agents are frequently
used, AAG-drug interactions may be of therapeutic impor-
tance.
Although binding to serum proteins may affect the disposi-
* Corresponding author. Mailing address: Department of Physiolog-
ical Sciences, College of Veterinary Medicine, Oklahoma State Uni-
versity, Stillwater, OK 74078. Phone: (405) 744-8093. Fax: (405)
744-8263. Electronic mail address: clarke@osuunx.ucc.okstate.edu.
t This is manuscript J 93-019 of the Oklahoma Agricultural Exper-
iment Station.
tion and tissue penetration of antibacterial agents (26), the
detrimental effects of protein binding on antibacterial activity
are primarily due to drug-protein interactions at the site of
infection, which is usually the interstitium. Study of these
interactions is frustrated by an inability to sample sufficient
quantities of interstitial fluid. Tissue chambers are hollow,
perforated devices that have been used as models to study
interstitial fluid and tissue penetration of xenobiotics (6). After
subcutaneous implantation, chambers fill with transudate,
which is in direct communication with the interstitial space (9).
Except for chloride levels in the tissue chamber, which are
higher than the corresponding levels in serum the electrolyte
composition of tissue chamber fluid approximates the hypoth-
esized composition of true interstitial fluid (12, 18). Both
chamber fluid and interstitial fluid have protein concentrations
that are considerably lower than the corresponding concentra-
tions in serum, although the concentrations in chamber fluid
are reported to be slightly greater than those in interstitial fluid
(18). Implanted tissue chambers therefore provide a model
which can be used to investigate the interactions between
proteins and drugs in the interstitial space. Experimental
infections established by inoculation of subcutaneous tissue
chambers (10, 11) provide a convenient source of infected
tissue fluid which can be subjected to in vitro analysis.
Pasteurella haemolytica is considered to be the most impor-
tant cause of bovine respiratory disease (8), which is respon-
sible for substantial economic losses to the cattle industry.
Selection of appropriate antimicrobial agents for treatment of
this disease is usually based on in vitro antimicrobial suscepti-
bility data (19). These data indicate that most isolates of P.
haemolytica are susceptible to erythromycin (17), a macrolide
antibiotic approved for this use by the U.S. Food and Drug
Administration. However, results of clinical trials have indi-
cated that the response of P. haemolytica to erythromycin may
be poorer than that predicted by in vitro data (23). Evidence
that raised concentrations of AAG in serum have been de-
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tected in calves following intratracheal inoculation of P. hae-
molytica (13) suggests that erythromycin may be inactivated in
vivo by binding to AAG and other macromolecules in infected
interstitium.
Therefore, the objective of the study was to determine the
effect of P. haemolytica infection on the proportion of eryth-
romycin bound to macromolecules in serum and tissue fluid
and to estimate the binding parameters describing binding
between erythromycin and bovine AAG and albumin.
MATERUILS AND METHODS
Animals. Six Hereford cross-bred calves, 4 to 8 months of
age and weighing from 100 to 225 kg, were used in the
experiment. Prior to use, the animals were dewormed with
fenbendazole (5 mg/kg of body weight; Safeguard; Hoechst-
Roussel Agri-Vet Co., Somerville, N.J.) and were observed on
a daily basis during a 2-week acclimation period to establish
that they were in good health. They were maintained in small
pens for the duration of the study and were fed grass and
alfalfa hay supplemented with a commercial grain mixture
containing 14% protein.
Implantation of tissue chambers. Two cup-shaped tissue
chambers (Delrin; E. I. du Pont de Nemours & Co., Wilming-
ton, Del.) measuring 46 mm (inner diameter) and 15 mm in
depth were implanted subcutaneously in each calf, one cham-
ber in each paralumbar fossa. Perforations in the walls and
bases of the chambers allowed unrestricted exchange of solutes
and cells between tissue chamber fluid and the surrounding
interstitial fluids. Chamber fluid could be aspirated by inserting
a needle through the skin and the silicone rubber (Silastic;
Dow Coming Corp., Midland, Mich.) membrane, which cov-
ered the top of the chamber. Tissue chamber assembly,
sterilization, surgical implantation, and collection of chamber
fluid samples have been described previously (12). The sterility
of the surgical technique was monitored approximately 1
month after implantation by culturing an aspirate of chamber
fluid aerobically and anaerobically on 5% sheep blood agar.
Inoculation and sample collection. Approximately 2 months
after implantation, preinoculation blood and chamber fluid
samples were collected. Five days later, all chambers were
inoculated with 1 ml of a 6-h culture of a field isolate of P.
haemolytica serotype 1 (14). The MIC of erythromycin for this
isolate has previously been determined to be 2 ,ug/ml (11).
Inocula were prepared by culture on supplemented brain heart
infusion agar; this was followed by suspension of bacteria in
phosphate-buffered saline (PBS) at a concentration of 3 x 106
CFU/ml as described previously (11). Four days after inocula-
tion, samples of blood and tissue chamber fluid were collected,
clarified through centrifugation and filtration, and frozen at
-20°C until analysis.
Dialysis experiments. The proportion of erythromycin
bound to proteins was determined by equilibrium dialysis.
Plexiglas dialysis chambers, each containing eight compart-
ments (200-,ul capacity on each side), were custom constructed.
Reconstituted cellulose membranes, 0.073 mm thick and with
a 6,000-molecular-weight cutoff (BelArt, Pequannock, N.J.),
separated protein-free and protein-containing compartments.
Two hundred microliters of sample (serum or chamber fluid
collected before and 4 days after inoculation) were dialyzed for
48 h against 200 ,u of 0.15 M phosphate buffer (pH 7.2)
containing different concentrations (0.5, 5.0, and 50.0 ,ug/ml) of
erythromycin in duplicate. The duration of incubation was
chosen on the basis of preliminary studies that investigated the
time necessary to achieve equilibrium. The concentrations of
erythromycin were within the range of those expected in serum
and tissues after intravascular (4) or intramuscular (5) admin-
istration of a recommended dose to cattle. Additional equilib-
rium controls (50,ug of erythromycin per ml) were included in
each assay and were dialyzed for 72 h.
Affinity- and capacity-binding parameters were determined
by dialyzing (48 h) different concentrations of erythromycin
(0.5, 5, 20, 40, 60, 80, 100pug/ml) in phosphate buffer against 1
mg of AAG (Sigma Chemical Co., St. Louis, Mo.) per ml or 3
g of albumin (Sigma Chemical Co.) per ml in buffer. Similar
concentrations of these proteins have been reported in the sera
of cattle inoculated with P. haemolytica (13, 25). The purity of
bovine AAG was confirmed by sodium dodecyl sulfate-polyac-
rylamide gel electrophoresis. Samples of albumin in PBS were
assayed by radial immunodiffusion assay (25) and were found
to be contaminated with very low levels of AAG (0.034 ± 0.019
mg of AAG per ml in samples containing 300 mg of albumin
per ml). These levels were considered inconsequential. An
equilibrium control (100,ug of erythromycin per ml) was
included in each assay and was dialyzed for 72 h. Each assay,
which included all concentrations of erythromycin, was re-
peated six times.
The desired erythromycin concentrations were obtained by
combining a constant amount of N-methyl-14C-labeled eryth-
romycin of 99% radiochemical purity (0.013,ug of 55 mCi/
mmol; New England Nuclear, Boston, Mass.) with various
amounts of unlabeled erythromycin (Gallimycin; Sanofi Ani-
mal Health, Overland Park, Kans.). Dialysis was performed at37°C for 48 h (72 h for equilibrium controls) in an oscillating
incubator (Gallenkamp Plus No. 1; Curtin Matheson, Carroll-
ton, Tex.). After dialysis, the radioactivity of 150 RI aspirated
from each compartment was measured by adding 5 ml of
scintillation cocktail (Atomlight; New England Nuclear) and
counting on a liquid scintillation counter (LS5000 TDC; Beck-
man Instruments, Fullerton, Calif.) for 5 min. Quench correc-
tion was achieved by the automatic external standard method.
Erythromycin stability.The stability of erythromycin under
dialysis conditions was monitored by bioassay by using Sarcina
lutea ATCC 9341 and the techniques described by Bennett et
al. (1). Standard concentration curves were constructed by
using 20, 10, 7, 5, 1, and 0.5 ,ug of erythromycin per ml and
were used to assay the test standard before and after incuba-
tion. A 5-,ug/ml test standard was divided into 30 aliquots; 10
aliquots were analyzed immediately and the concentrations
were determined from a standard curve, 10 aliquots were
incubated at 37°C in an oscillating incubator for 48 h, and the
remaining aliquots were placed in a refrigerator at 4°C for the
same period. In addition, fresh test standard (5 ,ug/ml) was
prepared and assayed concurrently with the postincubation
samples. After 48 h, the samples refrigerated at 4°C and the
samples incubated at 37°C were analyzed for their erythromy-
.cin concentrations. The average concentration in the fresh
samples was 5.07 ,ug/ml, while those in the refrigerated and
incubated samples were 4.98 and 4.94 ,ug/ml, respectively. An
analysis of variance indicated that there was no significant
difference between the means of the data for the three
treatment groups. From these results, it was concluded that,
over a period of 48 h, the degradation of erythromycin activity
was not significant at either 4 or 37°C.
Protein assay. Albumin and AAG concentrations were
assayed by the bromcresol green method (Centrifichem; Baker
Instruments Corp., Allentown, Pa.) and radial immunodiffu-
sion (25), respectively.
Data analyses. The degree of protein binding was calculated
by using the following equation: percent binding = (100 x
difference in activity between chamber sides)/activity on the
protein-containing side. The number of binding sites for
VOL. 38, 1994
ANTIMICROB. AGENTS CHEMOTHER.
TABLE 1. Proportional binding of erythromycin to serum or tissue
chamber fluid before and after inoculation of P. haemolytica
Binding site and erythromycin % Free erythromycina
concn (,ug/ml) Before inoculation After inoculation
Serum
0.5 0.52 ± 0.04 0.45 0.02b
5 0.55 ± 0.03 0.49 ± 0.03b
50 0.73 ± 0.03 0.71 ± 0.04
Chamber fluid
0.5 0.66 ± 0.04 0.66 ± 0.04
5 0.68 ± 0.07 0.65 ± 0.03
50 0.84 ± 0.04 0.81 ± 0.04
a Data are means ± standard deviations.
b Significantly different from preinoculation value.
erythromycin on AAG was determined by Scatchard analysis
(24), as were the initial estimates of binding-affinity constants.
Binding parameters of individual data sets were then deter-
mined by using a microcomputer program (3) to solve the
quadratic equation describing the relationship between total
and free drug concentration:
Cfree =
Ka - Ctot - 1 - Ka * Pt + '\'(Ka- Ct.t - 1 - Ka * Pt)' + 4 * K - Ct,t
2 Ka
where Ka is the binding-affinity constant, Pt is the protein
concentration, and Ctot and Cfree are the total and free drug
concentrations, respectively (2). Minimum sums of weighted
residuals (1/Cfree) were approached by using the Damping
Gauss-Newton fitting algorithm. Data describing the effects of
P. haemolytica on protein concentrations and the binding of
erythromycin to serum and chamber fluid were analyzed by
using paired t tests and two-factor (animal and chamber side)
analyses of variance, respectively. Differences were considered
significant at the P < 0.05 level.
RESULTS
Binding of erythromycin to macromolecules in serum and
chamber fluid varied widely depending on the matrix and
erythromycin concentration (Table 1). At two concentrations
of erythromycin (0.5 and 5.0 ,ug/ml), binding in serum was
significantly higher after inoculation, when the concentration
of AAG was higher (0.54 ± 0.04 mg/ml) compared with
preinoculation values (0.39 ± 0.11 mg/ml). Analysis of variance
revealed no difference in binding to macromolecules in cham-
ber fluids collected before and after inoculation, despite the
significant difference in AAG concentration (0.12 ± 0.02
mg/ml in noninfected chamber fluid versus 0.24 ± 0.05 mg/ml
in infected chamber fluid).
Binding of erythromycin to AAG was saturable between the
concentrations of 0.5 and 100 ,ug/ml (Table 2) and varied
between 38% free drug at 0.5 ,ug/ml and 73% free drug at 100
,ug/ml. Scatchard analysis of the data indicated a single binding
site with a mean binding-affinity constant of 6.45 x i04 ± 1.65
X 104 M-1 (Fig. 1). Equilibrium analysis of the binding by
using the quadratic equation describing the relationship be-
tween Ctot and Cfree yielded a similar mean estimate of binding
affinity (6.91 x 104 + 3.83 x 104 M-l) at a mean protein
concentration of 2.74 x 10-5 ± 6.09 x 10-5 M (Fig. 2).
Erythromycin was only slightly bound to albumin (Table 2),
TABLE 2. Proportional binding of erythromycin to
AAG and albumin
Erythromycin concn % Free erythromycin bound toa:
(t±g/m1) AAG Albumin
0.5 38±3 85±2
5 39±4 86±2
20 49±5 86±3
40 59±3 89±2
60 65±4 91±2
80 71±5 92±1
100 73±3 93±2
a Data are means ± standard deviations.
and no specific binding sites could be identified by Scatchard
analysis.
DISCUSSION
Most infections are not limited to the blood vascular system,
but are usually located in the interstitium. Therefore, although
drug-protein interactions in vascular blood may affect drug
disposition, interactions in tissues are most relevant to antimi-
crobial efficacy. Tissue chambers have been validated as a
model for studying interstitial infections (6, 7, 10, 11) and
contain fluid that is thought to be similar to the theoretical
composition of interstitial fluid (12). This characteristic and
the ease with which these chambers can be sampled make them
convenient models for studying drug-protein interactions in
interstitial fluid. Furthermore, the chamber model allows study
of protein binding in infected animals, which may be particu-
larly appropriate when a drug interacts with acute-phase
proteins, such as AAG. Previous studies have shown that
inoculation of P. haemolytica into subcutaneous tissue cham-
bers causes inflammatory changes that are similar to those
observed in the lungs of cattle with pneumonic pasteurellosis
(10, 11, 25). These changes include rapid sequestration of
degranulating neutrophils, deposition of fibrin, and leakage of
plasma proteins. Subcutaneous tissue chambers are slowly
equilibrating models and, therefore, represent inaccessible
tissue sites such as abscesses or consolidated lung lesions. Such
lesions are common in pneumonic pasteurellosis and are
believed to protect bacteria from therapeutic concentrations of
antibiotics.
Protein binding at the site of infection may be affected by
several factors including temperature, pH, drug concentration,
and protein concentration. Previous studies have indicated that
inoculation of chambers causes increased concentrations of
both AAG and albumin in chamber fluid and an increased
concentration of AAG in serum (25). Thus, infection is likely
to affect the binding of AAG to organic bases, such as
erythromycin. This was confirmed by the results of the present
study, in which a higher proportion of erythromycin was bound
in serum after inoculation than before inoculation. Although a
similar trend in binding was evident in chamber fluid, apparent
differences were not large enough to be declared statistically
significant. Assuming saturable binding, the effect of an in-
crease in protein concentration has a greater effect on propor-
tional binding when drug concentrations are relatively lower.
This relationship may explain the failure to identify significant
differences in binding in chamber fluids which contain less
protein and relatively more erythromycin or in serum at the
highest concentration of erythromycin.
By using the quadratic equation describing the relationship
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FIG. 1. Scatchard plot of mean data describing binding of erythromycin to AAG. The symbol [u] signifies the free concentration of
erythromycin, and Nu is the ratio of [u] to the AAG concentration. The plot was constructed by using mean data derived from six separate assays,
each of which included seven erythromycin concentrations (0.5, 5, 20, 40, 60, 80, and 100 ,jg/ml).
between total and free drug concentrations (2) and the affinity
constant derived by using that equation (6.91 x 104 M-1), the
theoretical proportions of free drug present at each of the
measured AAG concentrations in serum are similar to those
6E-05-
Ka = 6.91E+04
SE-05 - [AAG] = 2.74E-05
4E-05 -
3E-05
estimated by dialysis; at 5 ,ug of erythromycin per ml, infection
should cause a theoretical decrease in the proportion of free
drug from 62 to 54%. The slightly lower values (55 and 49% for
noninfected and infected sera, respectively) measured by dial-
I I I
4E-05 6E-05 8E-05
C-tot
FIG. 2. Quadratic relationship between free (C-free) and total (C-tot) concentrations of erythromycin. The plot was constructed by using mean
data derived from six separate assays, each of which included seven erythromycin concentrations (0.5, 5, 20, 40, 60, 80, and 100 jig/ml).
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ysis can be explained by the additional drug-binding activity of
albumin in serum. In contrast to serum, calculation of free
drug proportions at concentrations of AAG measured in
chamber fluids yields theoretical values of 84% for noninfected
chamber fluids and 73% for infected chamber fluids versus
corresponding measured values of 68 and 65%. Thus, theoret-
ical calculation of free drug concentrations underestimated
binding in chamber fluids and predicted a greater effect of
inoculation than was experimentally evident. Factors other
than changes in AAG concentration must have affected the
binding of erythromycin in chamber fluids after inoculation.
Previous studies have shown that inoculation of tissue cham-
bers with P. haemolytica causes a decrease in pH from 7.2 to 7.0
(10). Considering that binding of erythromycin is reported to
decrease at lower pH (16), the lower pH of infected chamber
fluid would oppose the effects of the higher AAG concentra-
tion and may explain why the free concentration of erythro-
mycin in infected chamber fluids was higher than expected.
Intramuscular administration of a recommended dose of 15
mg/kg to cattle results in concentrations in serum that fluctuate
between 3.5 and 0.5 ,ug/ml (5). Concentrations in tissue,
measured by using lung homogenates from animals sacrificed
at intervals for 24 h after drug dosing varied between 6 and 1
,ug/ml. Considering that concentrations in serum and tissue
barely exceeded the MIC for the P. haemolytica isolate used in
the present experiment (2 ,ug/ml), changes in protein binding
could decrease the free and pharmacologically active propor-
tion of erythromycin to concentrations that are lower than the
MIC. Therefore, although erythromycin is only moderately
protein bound, small changes in the concentration of AAG
could have significant effects on the in vivo efficacy of eryth-
romycin. This is especially true at low and therapeutically
relevant concentrations of erythromycin.
Depending on the drug concentration, erythromycin was
moderately bound to AAG but was only slightly bound to
albumin. These data are consistent with those presented in
previous reports indicating that AAG is the major binding
protein for erythromycin in human serum (15). Thus, erythro-
mycin follows the same pattern as many other basic xenobiotic
compounds in that it has a higher affinity for AAG than for
albumin, which binds acidic molecules more readily (15, 20).
The nonlinear regression analysis served to verify the Scat-
chard analysis and identify the possible existence of binding
sites other than those on AAG. A close correlation between
binding-affinity constants and protein concentrations con-
firmed that binding to other macromolecules was not substan-
tial, thus validating the dialysis methodology. Furthermore, the
nonlinear relationship between Ct.t and Cfree confirmed the
saturable nature of protein binding at the erythromycin con-
centrations tested.
In summary, values describing the binding of bovine AAG
and albumin to erythromycin approximate those reported in
humans. Differences in pre- and postinoculation binding are
significant at lower, therapeutically relevant concentrations of
erythromycin, probably because of the increased concentration
of AAG in serum. The soft-tissue infection model, established
by inoculation of subcutaneous tissue chambers, served as a
useful model for studying the effect of infection on drug-
protein interactions in interstitial fluid.
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